Periscope Capital’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Periscope Capital’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-297,500	Closed	-$3M	–	945
2022 Q4	$3M	Sell	297,500 -202,200	-40%	-$2.02M	0.13%	289
2022 Q3	$4.96M	Sell	499,700 -298	-0.1%	-$2.94K	0.14%	282
2022 Q2	$4.95M	Sell	499,998 -258,902	-34%	-$2.54M	0.13%	314
2022 Q1	$7.48M	Sell	758,900 -369	-0%	-$3.63K	0.19%	185
2021 Q4	$7.47M	Sell	759,269 -531	-0.1%	-$5.21K	0.2%	186
2021 Q3	$7.4M	Sell	759,800 -200	-0%	-$1.94K	0.22%	162
2021 Q2	$7.35M	Buy	760,000 +514,494	+210%	+$5M	0.24%	144
2021 Q1	$2.39M	Buy	+245,506	New	+$2.38M	0.09%	346

Periscope Capital's BIOT Position: Q1 2023 in Review

Periscope Capital sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 297,500 shares — an estimated $3M sold.

Periscope Capital first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $7.48M in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Periscope Capital reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Periscope Capital sold 297,500 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $3M.
Periscope Capital first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Periscope Capital's Biotech Acquisition Company Class A Ordinary Shares position peaked at $7.48M in Q1 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Periscope Capital's 13F filing for Q1 2023, filed 12 May 2023.